Avadel Pharmaceuticals plc (AVDL)
USD 8.7
(0.99%)
USD 8.7
(0.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -149.12 Million USD | -45.2% |
| 2022 | -97.6 Million USD | -10.83% |
| 2021 | -84.78 Million USD | -167.56% |
| 2020 | -34.97 Million USD | -120.41% |
| 2019 | -23.61 Million USD | 73.01% |
| 2018 | -95.14 Million USD | -182.26% |
| 2017 | 65.89 Million USD | 9.82% |
| 2016 | 5.73 Million USD | -49.1% |
| 2015 | 115.53 Million USD | 731.86% |
| 2014 | -94.74 Million USD | 14.26% |
| 2013 | -50.03 Million USD | 41.39% |
| 2012 | -8.36 Million USD | -264.23% |
| 2011 | -5.16 Million USD | 4.62% |
| 2010 | -4.04 Million USD | 10.03% |
| 2009 | -5.42 Million USD | -1.42% |
| 2008 | -11.29 Million USD | 66.62% |
| 2007 | -33.21 Million USD | -5.08% |
| 2006 | -33.19 Million USD | 21.19% |
| 2005 | -36.02 Million USD | -460.84% |
| 2004 | 9.34 Million USD | 471.74% |
| 2003 | -2.98 Million USD | -160.17% |
| 2002 | 1.23 Million USD | 38.66% |
| 2001 | -1.88 Million USD | 87.1% |
| 2000 | -14.99 Million USD | -153.59% |
| 1999 | -5.79 Million USD | 27.43% |
| 1998 | -8.25 Million USD | 9.18% |
| 1997 | -8.3 Million USD | -2.27% |
| 1996 | -8.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -25.49 Million USD | 9.11% |
| 2024 Q2 | -12.3 Million USD | 53.65% |
| 2023 Q2 | -48.94 Million USD | -76.61% |
| 2023 Q1 | -27.71 Million USD | -19.36% |
| 2023 FY | - USD | -45.2% |
| 2023 Q3 | -34.51 Million USD | 29.47% |
| 2023 Q4 | -24.91 Million USD | 27.81% |
| 2022 Q4 | -23.21 Million USD | -39.62% |
| 2022 Q2 | -26.09 Million USD | 7.89% |
| 2022 FY | - USD | -10.83% |
| 2022 Q3 | -16.62 Million USD | 36.29% |
| 2022 Q1 | -28.33 Million USD | -22.74% |
| 2021 FY | - USD | -167.56% |
| 2021 Q1 | -14.56 Million USD | -33.7% |
| 2021 Q2 | -21.64 Million USD | -48.61% |
| 2021 Q4 | -23.08 Million USD | 9.35% |
| 2021 Q3 | -25.46 Million USD | -17.63% |
| 2020 Q2 | -4.03 Million USD | -18.39% |
| 2020 Q1 | -3.4 Million USD | 45.53% |
| 2020 Q3 | -13.67 Million USD | -239.21% |
| 2020 Q4 | -10.89 Million USD | 20.29% |
| 2020 FY | - USD | -120.41% |
| 2019 Q3 | -1.44 Million USD | 44.84% |
| 2019 Q4 | -6.24 Million USD | -331.26% |
| 2019 Q2 | -2.62 Million USD | 40.78% |
| 2019 Q1 | -4.43 Million USD | 64.44% |
| 2019 FY | - USD | 73.01% |
| 2018 Q1 | -7.51 Million USD | -50.89% |
| 2018 FY | - USD | -182.26% |
| 2018 Q2 | -13.79 Million USD | -83.52% |
| 2018 Q3 | -19.33 Million USD | -40.08% |
| 2018 Q4 | -12.47 Million USD | 35.46% |
| 2017 Q2 | 22.52 Million USD | -24.55% |
| 2017 Q1 | 29.86 Million USD | 82.85% |
| 2017 FY | - USD | 9.82% |
| 2017 Q4 | -4.98 Million USD | -129.81% |
| 2017 Q3 | 16.71 Million USD | -25.8% |
| 2016 Q3 | 8.53 Million USD | -46.86% |
| 2016 Q2 | 16.05 Million USD | -6.71% |
| 2016 Q1 | 17.21 Million USD | -48.87% |
| 2016 FY | - USD | -49.1% |
| 2016 Q4 | 16.33 Million USD | 91.4% |
| 2015 Q3 | 33.87 Million USD | -2.12% |
| 2015 Q4 | 33.66 Million USD | -0.63% |
| 2015 Q1 | 19.53 Million USD | 413.58% |
| 2015 Q2 | 34.61 Million USD | 77.2% |
| 2015 FY | - USD | 731.86% |
| 2014 Q1 | -3.37 Million USD | 1.78% |
| 2014 FY | - USD | 14.26% |
| 2014 Q4 | -6.22 Million USD | -15.95% |
| 2014 Q2 | -3.76 Million USD | -11.53% |
| 2014 Q3 | -5.37 Million USD | -42.76% |
| 2013 Q1 | -3.1 Million USD | 75.3% |
| 2013 FY | - USD | 41.39% |
| 2013 Q3 | -4.93 Million USD | -9.89% |
| 2013 Q2 | -4.48 Million USD | -44.76% |
| 2013 Q4 | -3.43 Million USD | 30.37% |
| 2012 FY | - USD | -264.23% |
| 2012 Q4 | -12.55 Million USD | -202.87% |
| 2012 Q1 | 728 Thousand USD | 214.29% |
| 2012 Q2 | 34 Thousand USD | -95.33% |
| 2012 Q3 | -4.14 Million USD | -12294.12% |
| 2011 Q3 | 877 Thousand USD | 123.59% |
| 2011 FY | - USD | 4.62% |
| 2011 Q4 | -637 Thousand USD | -172.63% |
| 2011 Q1 | -4.75 Million USD | -228.87% |
| 2011 Q2 | -3.71 Million USD | 21.75% |
| 2010 Q2 | -5.01 Million USD | 7.71% |
| 2010 FY | - USD | 10.03% |
| 2010 Q4 | 3.68 Million USD | 195.57% |
| 2010 Q1 | -5.43 Million USD | -657.8% |
| 2010 Q3 | -3.85 Million USD | 23.08% |
| 2009 Q3 | -3.86 Million USD | -3.88% |
| 2009 FY | - USD | -1.42% |
| 2009 Q4 | 974 Thousand USD | 125.23% |
| 2009 Q1 | 1.21 Million USD | 179.34% |
| 2009 Q2 | -3.71 Million USD | -405.34% |
| 2008 Q1 | -3.16 Million USD | 50.49% |
| 2008 Q4 | -1.53 Million USD | 51.3% |
| 2008 Q3 | -3.15 Million USD | 13.22% |
| 2008 FY | - USD | 66.62% |
| 2008 Q2 | -3.63 Million USD | -14.69% |
| 2007 Q4 | -6.39 Million USD | 15.02% |
| 2007 Q3 | -7.52 Million USD | 39.57% |
| 2007 Q2 | -12.45 Million USD | -55.08% |
| 2007 Q1 | -8.02 Million USD | -25.83% |
| 2007 FY | - USD | -5.08% |
| 2006 FY | - USD | 21.19% |
| 2006 Q4 | -6.38 Million USD | 31.84% |
| 2006 Q3 | -9.36 Million USD | -15.97% |
| 2006 Q2 | -8.07 Million USD | 9.52% |
| 2006 Q1 | -8.92 Million USD | 8.54% |
| 2005 Q2 | -8.63 Million USD | 30.13% |
| 2005 Q3 | -10.78 Million USD | -24.93% |
| 2005 FY | - USD | -460.84% |
| 2005 Q1 | -12.35 Million USD | -238.18% |
| 2005 Q4 | -9.75 Million USD | 9.57% |
| 2004 Q1 | 4.34 Million USD | 68.95% |
| 2004 Q2 | -1.77 Million USD | -140.88% |
| 2004 Q4 | 8.94 Million USD | 517.85% |
| 2004 Q3 | -2.14 Million USD | -20.56% |
| 2004 FY | - USD | 471.74% |
| 2003 Q2 | -1.59 Million USD | 37.22% |
| 2003 Q1 | -1.95 Million USD | 52.29% |
| 2003 Q4 | 1.91 Million USD | 283.97% |
| 2003 FY | - USD | -160.17% |
| 2003 Q3 | -1.39 Million USD | 15.13% |
| 2002 FY | - USD | 38.66% |
| 2002 Q1 | 4.56 Million USD | 139.05% |
| 2002 Q2 | 4.99 Million USD | 9.6% |
| 2002 Q3 | 2.15 Million USD | -56.91% |
| 2002 Q4 | -2.98 Million USD | -355.15% |
| 2001 Q2 | 2.43 Million USD | -29.84% |
| 2001 Q4 | -11.68 Million USD | -544.99% |
| 2001 FY | - USD | 87.1% |
| 2001 Q3 | 2.62 Million USD | 7.89% |
| 2001 Q1 | 3.46 Million USD | 114.39% |
| 2000 Q4 | -24.1 Million USD | -903.57% |
| 2000 Q2 | 2.84 Million USD | 43.39% |
| 2000 Q1 | 1.98 Million USD | 117.97% |
| 2000 FY | - USD | -153.59% |
| 2000 Q3 | 3 Million USD | 5.56% |
| 1999 FY | - USD | 27.43% |
| 1999 Q4 | -11.03 Million USD | -753.55% |
| 1999 Q3 | 1.68 Million USD | 61.38% |
| 1999 Q2 | 1.04 Million USD | -19.54% |
| 1999 Q1 | 1.3 Million USD | 108.18% |
| 1998 Q2 | 2.7 Million USD | 200.0% |
| 1998 Q3 | 1.7 Million USD | -37.04% |
| 1998 FY | - USD | 9.18% |
| 1998 Q4 | -15.89 Million USD | -1034.76% |
| 1998 Q1 | -2.6 Million USD | 80.29% |
| 1997 Q4 | -13.7 Million USD | -1241.67% |
| 1997 FY | - USD | -2.27% |
| 1997 Q1 | 2.1 Million USD | 116.54% |
| 1997 Q2 | 1.3 Million USD | -38.1% |
| 1997 Q3 | 1.2 Million USD | -7.69% |
| 1996 Q2 | 900 Thousand USD | 325.0% |
| 1996 Q1 | -900 Thousand USD | 0.0% |
| 1996 Q3 | 700 Thousand USD | -22.22% |
| 1996 Q4 | -12.7 Million USD | -1914.29% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 236.411% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 12716.328% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 148.366% |
| Cosmos Health Inc. | -17.06 Million USD | -774.029% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -644.479% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 0.655% |
| Cronos Group Inc. | -72.14 Million USD | -106.69% |
| Incannex Healthcare Limited | -18.5 Million USD | -705.907% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -313.295% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 18465.148% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -4022.176% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -3799.286% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -3799.286% |
| SCYNEXIS, Inc. | 73.47 Million USD | 302.949% |
| Safety Shot Inc | -12.18 Million USD | -1123.822% |
| Theratechnologies Inc. | -10.31 Million USD | -1346.019% |
| Alpha Teknova, Inc. | -25.53 Million USD | -483.911% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -4538.314% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 191.546% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -3195.58% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1642.779% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 83.876% |
| Radius Health, Inc. | 38.31 Million USD | 489.259% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -6243.019% |
| Alvotech | -484.86 Million USD | 69.244% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 6.124% |
| SIGA Technologies, Inc. | 84.15 Million USD | 277.193% |
| Shineco, Inc. | -26.55 Million USD | -461.593% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2131.645% |
| Journey Medical Corporation | 1.92 Million USD | 7862.884% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -3440.588% |
| Embecta Corp. | 245.4 Million USD | 160.768% |
| Harrow Health, Inc. | 9.72 Million USD | 1633.734% |
| Procaps Group, S.A. | 104.02 Million USD | 243.352% |
| Biofrontera Inc. | -18.45 Million USD | -708.134% |
| DURECT Corporation | -24.68 Million USD | -504.136% |
| PainReform Ltd. | -9.56 Million USD | -1458.418% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 251.763% |
| OptiNose, Inc. | -15.55 Million USD | -858.818% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 667.746% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 513.88% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -20878.406% |
| ProPhase Labs, Inc. | -14.82 Million USD | -905.767% |
| Phibro Animal Health Corporation | 84.6 Million USD | 276.256% |
| Procaps Group S.A. | 104.02 Million USD | 243.352% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -1675.086% |
| Viatris Inc. | 3.51 Billion USD | 104.241% |
| Rockwell Medical, Inc. | -4.69 Million USD | -3076.928% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -14635.672% |
| Tilray Brands, Inc. | -72.84 Million USD | -104.721% |
| PetIQ, Inc. | 81.48 Million USD | 283.007% |
| Talphera, Inc. | -9.84 Million USD | -1415.19% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 135.839% |
| Alimera Sciences, Inc. | 7.27 Million USD | 2149.546% |
| Assertio Holdings, Inc. | -222.44 Million USD | 32.962% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -3636.861% |
| Hempacco Co., Inc. | -12.77 Million USD | -1067.477% |
| Alvotech | -484.86 Million USD | 69.244% |
| Lantheus Holdings, Inc. | 491 Million USD | 130.371% |
| Kamada Ltd. | 21.53 Million USD | 792.51% |
| Currenc Group, Inc. | -1.9 Million USD | -7746.314% |
| Indivior PLC | 66 Million USD | 325.947% |
| Evoke Pharma, Inc. | -7.29 Million USD | -1944.967% |
| Flora Growth Corp. | -45.87 Million USD | -225.104% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -644.479% |
| Evolus, Inc. | -41.81 Million USD | -256.673% |
| HUTCHMED (China) Limited | 25.52 Million USD | 684.162% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 161.759% |
| Akanda Corp. | -27.73 Million USD | -437.665% |